Clinical Catch-Up: December 21-25 | BioSpace
The Pharma Data
DECEMBER 27, 2020
Taysha Gene Therapies announced that Queen’s University in Ontario, Canada, received Clinical Trial Application (CTA) approval from Health Canada for its Phase I/II trial of TSHA-101 for infantile GM2 gangliosidosis. RESTORE-1 is a Phase II trial of an intracerebral AAV-based gene therapy for Parkinson’s disease.
Let's personalize your content